Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Other Non-Current Assets (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Other Non-Current Assets for 10 consecutive years, with $978000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 74.18% to $978000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $978000.0 through Dec 2025, down 74.18% year-over-year, with the annual reading at $978000.0 for FY2025, 74.18% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $978000.0 at Intellia Therapeutics, down from $2.9 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $5.2 million in Q3 2021, with the low at $978000.0 in Q4 2025.
  • Average Other Non-Current Assets over 4 years is $3.7 million, with a median of $3.7 million recorded in 2024.
  • The sharpest move saw Other Non-Current Assets surged 77.22% in 2021, then plummeted 74.18% in 2025.
  • Over 4 years, Other Non-Current Assets stood at $5.2 million in 2021, then decreased by 12.53% to $4.5 million in 2023, then dropped by 16.16% to $3.8 million in 2024, then tumbled by 74.18% to $978000.0 in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $978000.0, $2.9 million, and $3.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.